Structural optimization and in vitro profiling of N-phenylbenzamide-based farnesoid X receptor antagonists

Add time:07/15/2019    Source:sciencedirect.com

Activation of the nuclear farnesoid X receptor (FXR) which acts as cellular bile acid sensor has been validated as therapeutic strategy to counter liver disorders such as non-alcoholic steatohepatitis by the clinical efficacy of obeticholic acid. FXR antagonism, in contrast, is less well studied and potent small molecule FXR antagonists are rare. Here we report the systematic optimization of a novel class of FXR antagonists towards low nanomolar potency. The most optimized compound antagonizes baseline and agonist induced FXR activity in a full length FXR reporter gene assay and represses intrinsic expression of FXR regulated genes in hepatoma cells. With this activity and a favorable toxicity-, stability- and selectivity-profile it appears suitable to further study FXR antagonism in vitro and in vivo.

We also recommend Trading Suppliers and Manufacturers of N-(4-bromo-2-methylphenyl)[1,1'-biphenyl]-4-carboxamide (cas 349407-34-7). Pls Click Website Link as below: cas 349407-34-7 suppliers

Prev:The Bcl-2/Bcl-xL inhibitor BH3I-2′ affects the dynamics and subcellular localization of sumoylated proteins
Next:The genetic activity of 6-N-HYDROXYLAMINOPURINE (cas 5667-20-9) in Aspergillus nidulans)